Humulin R is a drug owned by Eli Lilly And Co. It is protected by 1 US drug patent filed in 2016 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 09, 2024. Details of Humulin R's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7291132 | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(4 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Humulin R's patents.
Latest Legal Activities on Humulin R's Patents
Given below is the list of recent legal activities going on the following patents of Humulin R.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Apr, 2019 | US7291132 |
| Post Issue Communication - Certificate of Correction | 09 Sep, 2008 | US7291132 |
| Post Issue Communication - Certificate of Correction | 23 Jun, 2008 | US7291132 |
| Patent Issue Date Used in PTA Calculation Critical | 06 Nov, 2007 | US7291132 |
| Recordation of Patent Grant Mailed Critical | 06 Nov, 2007 | US7291132 |
| Email Notification Critical | 19 Oct, 2007 | US7291132 |
| Issue Notification Mailed Critical | 17 Oct, 2007 | US7291132 |
| Dispatch to FDC | 04 Oct, 2007 | US7291132 |
| Application Is Considered Ready for Issue Critical | 01 Oct, 2007 | US7291132 |
| Issue Fee Payment Received Critical | 28 Sep, 2007 | US7291132 |
FDA has granted several exclusivities to Humulin R. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Humulin R, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Humulin R.
Exclusivity Information
Humulin R holds 1 exclusivities. All of its exclusivities have expired in 2014. Details of Humulin R's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NR(NR) | Mar 25, 2014 |
US patents provide insights into the exclusivity only within the United States, but Humulin R is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Humulin R's family patents as well as insights into ongoing legal events on those patents.
Humulin R's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Humulin R's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 09, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Humulin R Generics:
There are no approved generic versions for Humulin R as of now.
Alternative Brands for Humulin R
Humulin R which is used for managing symptoms of depression and anxiety., has several other brand drugs using the same active ingredient (Insulin Recombinant Human). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Lilly |
| ||
| Mannkind |
| ||
| Pfizer |
|
About Humulin R
Humulin R is a drug owned by Eli Lilly And Co. It is used for managing symptoms of depression and anxiety. Humulin R uses Insulin Recombinant Human as an active ingredient. Humulin R was launched by Lilly in 2015.
Approval Date:
Humulin R was approved by FDA for market use on 29 December, 2015.
Active Ingredient:
Humulin R uses Insulin Recombinant Human as the active ingredient. Check out other Drugs and Companies using Insulin Recombinant Human ingredient
Treatment:
Humulin R is used for managing symptoms of depression and anxiety.
Dosage:
Humulin R is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 500 UNITS/ML | INJECTABLE | Prescription | INJECTION |